

By email

Dr Richard Jennings Group CMO **GESH**

12 March 2025

Dear Dr Jennings

I am writing on behalf of Merton, Sutton, Wandsworth and Surrey and Sussex LMCs who have been made aware of requests from non-obesity specialists that GPs prescribe GLP-1 receptor agonists e.g. Wegovy, Saxenda and Mounjaro.

The requests often quote NICE guidance in relation to the provision of this intervention in communications which have been shared with the patient. The requests come from multiple specialities including cardiology, endocrinology, etc.

South West London Integrated Medicines Optimisation Committee has stated that 'Prescribing of Semaglutide (Wegovy®) and Liraglutide (Saxenda®) for weight loss is restricted to tier 3 and 4 weight management services at St George's hospital, in line with the criteria set and therefore should not be issued in primary care. Mounjaro should not be provided in any other setting for obesity management.

The LMCs would like confirmation from all trusts that this practice will stop and that this will be communicated to all consultants. Any consultants who consider the patient would benefit from obesity management can and must refer the patient themselves to the hospital-based service.

The LMCs recognise the difficulty in managing this condition but consider that all must play their part in securing safe and cost-effective services based on a principle of proportionate care to those most in need.

Yours sincerely

Nicola Rice

Assistant Director of Primary Care

Londonwide LMCs

Noleeo



